Browse articles on EyeWorld.org from the Cornea section. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
When treating dry eye patients, it’s possible to encounter patients who do not respond to treatment. Two experts discussed how to proceed in approaching these patients and getting them the care they need.
While this bonus issue delves into the diverse aspects of dry eye, the EyeWorld Editorial Board thought it was important to call out dry eye masqueraders—conditions that might initially seem like dry eye but aren’t. EyeWorld spoke with one physician to gain insights on these dry eye decoys.
Astigmatism, whether regular or irregular, is something that many ophthalmologists are familiar with. Three experts delved into the issue and how to deal with it, particularly highlighting the pinhole pupilloplasty technique.
Cornea Editor Julie Schallhorn, MD, shared the story of a personal friend of hers to introduce the “must-read” article on corneal side effects of cancer-specific therapies, also mentioning the articles on Sjogren’s disease and pinhole apertures in the management of irregular corneas.
The president and CEO of the Sjögren’s Foundation as well as two ophthalmologists spoke about the diagnosis journey, available treatments, and future hopes for patients with Sjögren’s disease.
Antibody drug conjugates, an emerging area in cancer therapy, can pose a risk to the eye and cause adverse ocular events. Several experts discussed the research, what they’ve seen in terms of side effects, and considerations for patients taking these drugs and the eyecare providers monitoring them.
Results from the Zoster Eye Disease Study (ZEDS) were first presented last year. This randomized clinical trial looked at the use of low dose valacyclovir for reducing complications with herpes zoster ophthalmicus. Two cornea specialists spoke to EyeWorld about the results, highlighting recently published papers on findings from the study.
For about 7 years, there has been one FDA approved treatment for neurotrophic keratitis (NK): Oxervate (cenegermin-bkbj, Dompe). Before that, there was nothing. Now pharmaceutical options for NK—and persistent epithelial corneal defect (PCED) more generally—in the pipeline number about a half dozen.
Cornea Editor Julie Schallhorn, MD, gave a preview of the articles in the section and talked about the current climate for institutional funding for research.
With dry eye presenting as an increasingly common issue, many companies are exploring options to treat these patients. New products in development are seeking to address different aspects of dry eye, with various amechanisms of action. Three specialists discussed some of these.
Get the latest ophthalmology news delivered to your inbox every Friday.